

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 620-301  
C# M#

Davis et al


TC/A.U. 1647

Serial No. 10/822,677

Examiner: NICHOLS

Filed: April 13, 2004

Date: October 7, 2005

Title: USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC  
FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 4 minus highest number  
previously paid for 20 (at least 20) = 0 x \$50.00 \$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment 2 minus highest number  
previously paid for 4 (at least 3) = 0 x \$200.00 \$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add  
\$360.00 (1051)/\$180.00 (2051) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s)  
One Month Extension \$120.00 (1251)/\$60.00 (2251)  
Two Month Extensions \$450.00 (1252)/\$225.00 (2252)  
Three Month Extensions \$1020.00 (1253)/\$510.00 (2253)  
Four Month Extensions \$1590.00 (1254)/\$795.00 (2254) \$ 1020.00

Terminal disclaimer enclosed, add \$130.00 (1814)/\$65.00 (2814) \$

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806) \$

Assignment Recording Fee \$40.00 (8021) \$


Other: \$

**TOTAL FEE ENCLOSED \$ 1020.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor  
Arlington, Virginia 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:ppNIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Davis et al

Atty. Ref.: 620-301; Confirmation No. 3671

Appl. No. 10/822,677

TC/A.U. 1647

Filed: April 13, 2004

Examiner: NICHOLS

For: USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC  
FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

\* \* \* \* \*

October 7, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT**

Responsive to the Office Action dated April 8, 2005, entry and consideration of the following amendments and remarks are requested; the period for response having been extended up to and including Monday, October 11, 2005, by submission of the requisite petition and fee, attached.

10/12/2005 HALI11 00000088 10822677

01 FC:1253

1020.00 OP

1000928